Cerebrospinal fluid B cells and disease progression in multiple sclerosis - A longitudinal prospective study
Open Access
- 4 August 2017
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 12 (8) , e0182462
Abstract
There is evidence that B cells play an important role in disease pathology of multiple sclerosis (MS). The aim of this prospective observational study was to determine the predictive value of cerebrospinal fluid (CSF) B cell subtypes in disease evolution of patients with MS. 128 patients were included between 2004 and 2012. Median follow up time was 7.9 years (range 3.3–10.8 years). 10 patients were lost to follow-up. 32 clinically isolated syndrome- (CIS), 25 relapsing remitting MS- (RRMS), 2 secondary progressive MS- (SPMS) and 9 primary progressive MS- (PPMS) patients were included. The control group consisted of 40 patients with other neurological diseases (OND). CSF samples were analyzed for routine diagnostic parameters. B cell phenotypes were characterized by flow cytometry using CD19 and CD138 specific antibodies. Standardized baseline brain MRI was conducted at the time of diagnostic lumbar puncture. Main outcome variables were likelihood of progressive disease course, EDSS progression, conversion to clinical definite MS (CDMS) and relapse rate. CSF mature B cells (CD19+CD138-) were increased in bout-onset MS compared to PPMS (p<0.05) and OND (p<0.001), whereas plasma blasts (CD19+CD138+) were increased in bout-onset MS (p<0.001) and PPMS (p<0.05) compared to OND. CSF B cells did not predict a progressive disease course, EDSS progression, an increased relapse rate or the conversion to CDMS. Likelihood of progressive disease course (p<0.05) and EDSS (p<0.01) was predicted by higher age at baseline, whereas conversion to CDMS was predicted by a lower age at onset (p<0.01) and the presence of ≥9 MRI T2 lesions (p<0.05). We detected significant differences in the CSF B cell subsets between different clinical MS subtypes and OND patients. CSF B cells were neither predictive for disease and EDSS progression nor conversion to CDMS after a CIS.Keywords
Funding Information
- Austrian Federal Ministry of Science, Research and Economy
- Austrian Multiple Sclerosis Research Society
This publication has 42 references indexed in Scilit:
- The utility of cerebrospinal fluid analysis in patients with multiple sclerosisNature Reviews Neurology, 2013
- Predictors of Conversion to Multiple Sclerosis in Patients with Clinical Isolated Syndrome Using the 2010 Revised McDonald CriteriaISRN Neurology, 2012
- The evidence for a role of B cells in multiple sclerosisNeurology, 2012
- Related B cell clones that populate the CSF and CNS of patients with multiple sclerosis produce CSF immunoglobulinJournal of Neuroimmunology, 2011
- Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteriaAnnals of Neurology, 2011
- The Chemokine CXCL13 Is a Prognostic Marker in Clinically Isolated Syndrome (CIS)PLOS ONE, 2010
- Clinical predictors of early second event in patients with clinically isolated syndromeJournal of Neurology, 2009
- Cerebrospinal Fluid B Cells Correlate with Early Brain Inflammation in Multiple SclerosisPLOS ONE, 2008
- The Immunopathology of Multiple Sclerosis: An OverviewBrain Pathology, 2007
- Rating neurologic impairment in multiple sclerosisNeurology, 1983